In the absence of a cohesive workflow guiding the use of PARPi in ovarian cancer since the 2022 FDA approval withdrawals, what is your general approach to PARPi usage in the front-line and recurrent setting?  

Answer from: at Academic Institution
at Baptist Medical Group
Excellent summary
at BayCare Medical Group
Thanks @Dario!
Sign in or Register to read more